Year-end Sale % OFF 
Abstract
In May 2010, denosumab (Prolia; Amgen) was granted marketing authorization by the European Commission for the treatment of postmenopausal women with osteoporosis who are at increased risk of fracture, and for the treatment of bone loss associated with hormone ablation therapy in men with prostate cancer at increased risk of fracture. Shortly after, in June 2010, denosumab was approved by the US FDA for the treatment of postmenopausal women with osteoporosis at high risk of fracture.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
